Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,074 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Is guideline-adherent adjuvant treatment an equal alternative for patients aged >65 who cannot participate in adjuvant clinical breast cancer trials? A retrospective multi-center cohort study of 4,142 patients.
Van Ewijk R, Wöckel A, Gundelach T, Hancke K, Janni W, Singer S, Kreienberg R, Blettner M, Schwentner L. Van Ewijk R, et al. Among authors: singer s. Arch Gynecol Obstet. 2015 Mar;291(3):631-40. doi: 10.1007/s00404-014-3438-7. Epub 2014 Sep 2. Arch Gynecol Obstet. 2015. PMID: 25178186
Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II.
Schwentner L, Van Ewijk R, Kühn T, Flock F, Felberbaum R, Blettner M, Kreienberg R, Janni W, Wöckel A, Singer S. Schwentner L, et al. Among authors: singer s. Support Care Cancer. 2016 Jun;24(6):2759-66. doi: 10.1007/s00520-016-3088-3. Epub 2016 Jan 27. Support Care Cancer. 2016. PMID: 26816089
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial.
Schwentner L, Harbeck N, Singer S, Eichler M, Rack B, Forstbauer H, Wischnik A, Scholz C, Huober J, Friedl TW, Weissenbacher T, Härtl K, Kiechle M, Janni W, Fink V. Schwentner L, et al. Among authors: singer s. Breast. 2016 Jun;27:69-77. doi: 10.1016/j.breast.2016.03.003. Epub 2016 Apr 4. Breast. 2016. PMID: 27054751 Clinical Trial.
Which patient- and physician-related factors are associated with guideline adherent initiation of adjuvant endocrine therapy? Results of the prospective multi-centre cohort study BRENDA II.
Stüber T, van Ewijk R, Diessner J, Kühn T, Flock F, Felberbaum R, Blettner M, Kreienberg R, Janni W, Wöckel A, Singer S, Schwentner L. Stüber T, et al. Among authors: singer s. Breast Cancer. 2017 Mar;24(2):281-287. doi: 10.1007/s12282-016-0701-8. Epub 2016 May 19. Breast Cancer. 2017. PMID: 27193566
Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial.
Eichler M, Singer S, Janni W, Harbeck N, Rack B, Augustin D, Wischnik A, Kiechle M, Ettl J, Scholz C, Fink V, Schwentner L. Eichler M, et al. Among authors: singer s. Breast Cancer. 2017 Mar;24(2):319-325. doi: 10.1007/s12282-016-0706-3. Epub 2016 Jun 4. Breast Cancer. 2017. PMID: 27262301 Clinical Trial.
The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Leinert E, Singer S, Janni W, Harbeck N, Weissenbacher T, Rack B, Augustin D, Wischnik A, Kiechle M, Ettl J, Fink V, Schwentner L, Eichler M. Leinert E, et al. Among authors: singer s. Clin Breast Cancer. 2017 Apr;17(2):100-106. doi: 10.1016/j.clbc.2016.10.008. Epub 2016 Oct 19. Clin Breast Cancer. 2017. PMID: 27884722
2,074 results